Compare DUOT & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOT | QNCX |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 158.9M | 167.0M |
| IPO Year | 2017 | 2019 |
| Metric | DUOT | QNCX |
|---|---|---|
| Price | $7.51 | $0.10 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $14.00 | $10.00 |
| AVG Volume (30 Days) | 662.6K | ★ 16.2M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.90 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,280,885.00 | N/A |
| Revenue This Year | $286.66 | N/A |
| Revenue Next Year | $44.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.84 | $0.08 |
| 52 Week High | $12.17 | $4.55 |
| Indicator | DUOT | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 42.47 | 29.94 |
| Support Level | $6.99 | $0.09 |
| Resistance Level | $8.45 | $0.98 |
| Average True Range (ATR) | 0.39 | 0.01 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 32.72 | 66.12 |
Duos Technologies Group Inc operating under its brand name duostech, designs, develops, deploys and operates intelligent technology solutions supporting rail, logistics and intermodal businesses that streamline operations, improve safety and reduce costs. The company's main offering, the Railcar Inspection Portal (RIP), provides both freight and transit railroad customers and select government agencies the ability to conduct fully automated railcar inspections of trains that are moving at full speed. It has also developed the Automated Logistics Information System (ALIS) which automates gatehouse operations where transport trucks enter and exit large logistics and intermodal facilities. Its segments are Rail, Commercial, Governments, Banking and AI.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.